Commentary
Video
Author(s):
Roger Li, MD, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820).
Roger Li, MD, a genitourinary oncologist at Moffitt Cancer Center, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820) examining TAR-210 vs intravesical chemotherapy in patients with non–muscle-invasive bladder cancer.